RxDoctor Payments Data

Sharon Dilley, MD

Internal Medicine · Jefferson, NCNPI 1033187323

Payments from drug & device makers

$778in general payments, 2019–2025

Across 42 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$213
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$156
  • Novo Nordisk$77
  • GSK$67
  • Lilly USA, LLC$60
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$52
  • plus $154 from 7 others

What the payments were for

  • Food & beverage$778100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$778 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$68,155
Medicare patients
245
Services billed
1,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$144,767
EliquisApixaban133$130,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$45,325
TrulicityDulaglutide36$38,175
JardianceEmpagliflozin29$33,521
MounjaroTirzepatide24$24,025
JanuviaSitagliptin Phosphate26$22,639
FarxigaDapagliflozin Propanediol18$17,562
XareltoRivaroxaban11$16,564
Tresiba Flextouch U-100Insulin Degludec23$16,315
MyrbetriqMirabegron25$14,178
Breo ElliptaFluticasone/Vilanterol24$12,321
Spiriva RespimatTiotropium Bromide11$10,614
Aimovig AutoinjectorErenumab-Aooe13$9,385
Xtampza ErOxycodone Myristate13$8,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$77$144,767124 claims
Lilly USA, LLCTrulicity, Mounjaro$60$62,19960 claims
GSKTrelegy Ellipta, Breo Ellipta$67$57,64578 claims
AstraZenecaFarxiga$14$17,56218 claims
AbbVieSynthroid$17$4,43348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Jefferson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →